Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
First data from EMPRISE Real-World Evidence study in type 2 diabetes reveals risk reduction for patient on Empagliflozin compared to DPP-4 inhibitors CONTEXT: Interim analysis of the EMPRISE real-world evidence Continue Reading
